Generic name: exenatide
Dosage form: injection
This dosage information does not include all the information needed to use Bydureon safely and effectively. See full prescribing information for Bydureon.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
BYDUREON (2 mg per dose) should be administered once every seven days (weekly). The dose can be administered at any time of day, with or without meals.
If a dose is missed, it should be administered as soon as noticed, provided the next regularly scheduled dose is due at least three days later. Thereafter, patients can resume their usual dosing schedule of once every seven days (weekly).
If a dose is missed and the next regularly scheduled dose is due one or two days later, the patient should not administer the missed dose and instead resume BYDUREON with the next regularly scheduled dose.
BYDUREON is intended for patient self-administration. BYDUREON is provided in a single-dose tray containing: one vial of 2 mg exenatide, one vial connector, one prefilled diluent syringe and two needles (one provided as a spare) [see How Supplied/Storage and Handling (16.1)]. Do not substitute needles or any other components in the tray.
BYDUREON must be injected immediately after the powder is suspended in the diluent and transferred to the syringe. BYDUREON is administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. Advise patients to use a different injection site each week when injecting in the same region. BYDUREON must not be administered intravenously or intramuscularly.
See the BYDUREON Instructions for Use for complete administration instructions with illustrations. The instructions can also be found at www.bydureon.com.
Changing from BYETTA to BYDUREON
Prior treatment with BYETTA is not required when initiating BYDUREON therapy. If the decision is made to start BYDUREON in an appropriate patient already taking BYETTA, BYETTA should be discontinued. Patients changing from BYETTA to BYDUREON may experience transient (approximately two weeks) elevations in blood glucose concentrations.